Human antibodies specific for TGFβ2
US7368111B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jul 23, 2003 |
| Grant date | May 6, 2008 |
| Priority date | — |
| Expiry date | Sep 24, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/622
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Specific binding members comprising human antibody antigen binding domains specific for human transforming growth factor beta (TGFβ) bind specifically isoforms TGFβ2 and TGFβ1 or both, preferentially compared with TGFβ3. Specific binding members may be isolated and utilized in the treatment of disease, particularly fibrotic disease and also immune/inflammatory diseases. Therapeutic utility is demonstrated using in vitro and in vivo models. Full sequence and binding information is provided, including epitope sequence information for particularly advantageous specific binding member which binds the active form of TGFβ2, neutralizing its activity, but does not bind the latent member.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.